Seres Therapeutics, Inc. is a USA-based pharmaceutical company with a medium risk ESG score of 26.2. Specializing in microbiome therapeutics, Seres Therapeutics focuses on developing ecobiotic microbiome drugs to restore health by repairing dysbiotic microbiomes. One of their key products, SER-109, targets preventing recurrences of Clostridium difficile infection (CDI). With a strong focus on sustainability and governance, Seres Therapeutics is at the forefront of microbiome therapeutic development in the pharmaceutical industry.